Merck & Co., Inc. $MRK Stock Purchased by Investment Partners LTD.

Investment Partners LTD. grew its holdings in Merck & Co., Inc. (NYSE:MRK) by 72.9% during the third quarter, Holdings Channel.com reports. The firm owned 8,813 shares of the company’s stock after acquiring an additional 3,715 shares during the period. Investment Partners LTD.’s holdings in Merck & Co., Inc. were worth $1,281,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in MRK. Dimensional Fund Advisors LP increased its position in shares of Merck & Co., Inc. by 23.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company’s stock worth $1,858,938,000 after purchasing an additional 2,969,856 shares during the last quarter. Bank of America Corp DE increased its stake in Merck & Co., Inc. by 10.5% in the first quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock valued at $3,701,831,000 after acquiring an additional 2,919,780 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Merck & Co., Inc. by 263.7% in the second quarter. Assenagon Asset Management S.A. now owns 2,702,992 shares of the company’s stock worth $347,334,000 after acquiring an additional 1,959,778 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Merck & Co., Inc. by 2.3% in the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after acquiring an additional 1,934,312 shares during the last quarter. Finally, SEB Asset Management AB acquired a new position in shares of Merck & Co., Inc. during the first quarter worth $197,550,000. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Up 2.3%

Shares of NYSE MRK opened at $149.75 on Friday. Merck & Co., Inc. has a 12-month low of $82.01 and a 12-month high of $156.92. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The stock has a market cap of $369.46 billion, a PE ratio of 154.38, a P/E/G ratio of 6.52 and a beta of 0.21. The company has a 50-day moving average of $146.90 and a 200 day moving average of $126.69.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.09 by $0.40. The company had revenue of $18.09 billion for the quarter, compared to analyst estimates of $17.33 billion. Merck & Co., Inc. had a return on equity of 16.56% and a net margin of 3.64%. Merck & Co., Inc.’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter last year, the company earned $2.58 EPS. As a group, sell-side analysts predict that Merck & Co., Inc. will post 2.81 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP David Maraldo sold 18,706 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the sale, the executive vice president directly owned 18,212 shares in the company, valued at approximately $2,344,248.64. This trade represents a 50.67% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Chirfi Guindo sold 15,000 shares of Merck & Co., Inc. stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the completion of the transaction, the executive vice president directly owned 46,613 shares of the company’s stock, valued at $6,106,303. This trade represents a 24.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 228,238 shares of company stock worth $29,977,783. Corporate insiders own 0.17% of the company’s stock.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Strong Q3 results and raised outlook: Merck reported adjusted earnings of $2.49 per share versus the $2.09 analyst consensus, while revenue rose 4.7% year over year to $18.09 billion, ahead of estimates. Management raised its 2026 sales and adjusted-profit outlook, providing the main catalyst for the stock’s advance. Merck tops quarterly estimates and hikes profit outlook
• Positive Sentiment: Growth beyond Keytruda: Keytruda, including the newer Qlex formulation, delivered stronger-than-expected sales, while WINREVAIR continued to expand rapidly. Newer product launches are helping offset losses from generic competition and support Merck’s growth outlook. Merck Q3 earnings call highlights pipeline progress and raised outlook
• Positive Sentiment: Pipeline progress: Positive Phase 3 endometrial-cancer data for Keytruda and sacituzumab tirumotecan, along with FDA priority review for the latter, strengthens confidence in Merck’s oncology pipeline and its ability to address future revenue pressure. Merck Phase 3 endometrial cancer data and FDA review
• Positive Sentiment: Supportive analyst action: Guggenheim raised its price target to $171 and maintained a buy rating, indicating additional potential upside based on the earnings and pipeline outlook.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on MRK shares. Argus raised their target price on Merck & Co., Inc. from $145.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, August 25th. Cantor Fitzgerald upped their price objective on shares of Merck & Co., Inc. from $120.00 to $145.00 and gave the stock a “neutral” rating in a research report on Thursday, October 8th. Barclays boosted their price objective on shares of Merck & Co., Inc. from $150.00 to $180.00 and gave the company an “overweight” rating in a research report on Monday, October 26th. Wall Street Zen lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Finally, Berenberg Bank boosted their target price on shares of Merck & Co., Inc. from $127.00 to $137.00 and gave the company a “hold” rating in a research note on Friday, September 11th. Seventeen investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $156.08.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.